type 2 diabetes diabetes
Conditions
Interventions
Obtain biopsy tissue from four or more locations from the ileum or descending colon that the gastrointestinal endoscopist determines to be normal mucosa using standard biopsy forceps.
biopsy
Sponsors
Sakaguchi Kazuhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Metformin oral group 1. patients scheduled to undergo lower gastrointestinal endoscopy 2. patients with type 2 diabetes who have been taking metformin at least 1000 mg/day for more than 1 month 3. patients who are expected to take no less than 1000 mg/day of metformin until they undergo lower gastrointestinal endoscopy 4. patients aged 20 years or older but less than 75 years. 5. patients who have given their written consent for the study. Metformin non-medication group 1. patients scheduled to undergo lower gastrointestinal endoscopy 2. patients with type 2 diabetes who have not taken metformin for more than 1 month. 3. patients who are not expected to start metformin for a period of time before undergoing lower gastrointestinal endoscopy 4. patients aged 20 years or older but less than 75 years. 5. patients who have given their written consent for the study.
Exclusion criteria
Exclusion criteria: 1. pregnant women, lactating women, and women who may become pregnant. 2. patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) or with a history of such disease. 3. patients with a history of gastrointestinal tract surgery (excluding endoscopic mucosal resection) 4. patients with suspected gastrointestinal tract infections 5. patients with predisposition to bleeding (platelet abnormality: von Willebrand disease, coagulation abnormality: hemophilia, vascular abnormality: IgA) Vascular abnormalities: IgA vasculitis, etc.) 6. patients taking two or more anticoagulants or antiplatelet agents 7. patients suffering from dementia or psychiatric disease 8. patients with HBV, HCV, or HIV. 9. other patients who are judged to be inappropriate by the person in charge of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene expression level of GLUT2 (Glucose transporter 2) | — |
Secondary
| Measure | Time frame |
|---|---|
| Expression site of GLUT2 (luminal side, basement membrane side) | — |
Contacts
Public ContactJun Ito
Kobe University Hospital
Outcome results
None listed